Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

@article{HammondThelin2010PhaseIA,
  title={Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies},
  author={Lisa A. Hammond-Thelin and Melanie B. Thomas and Michiko Iwasaki and James L Abbruzzese and Yvonne Lassere and Christina A. Meyers and Paulo M.G. Hoff and Johann Sebastian de Bono and Jody D Norris and Hitoshi Matsushita and Akira Mita and Eric K. Rowinsky},
  journal={Investigational New Drugs},
  year={2010},
  volume={30},
  pages={316-326}
}
Background TAS-106 is a novel nucleoside analog that inhibits RNA polymerases I, II and II and has demonstrated robust antitumor activity in a wide range of models of human cancer in preclinical studies. This study was performed to principally evaluate the feasibility of administering TAS-106 as a bolus intravenous (IV) infusion every 3 weeks. Patients and Methods Patients with advanced solid malignancies were treated with escalating doses of TAS-106 as a single bolus IV infusion every 3 weeks… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Intracellular metabolism and actions of a novel antitumor nucleoside, 1-(3′-Cethynyl-β-D-ribo-pentofuranosyl) cytosine (Ecyd, TAS-106)

  • A Azuma, T Emura, P Huang, W Plunkett
  • Proc Am. Assoc Cancer Res
  • 1999
Highly Influential
6 Excerpts

Preclinical pharmacology and mechanisms of action

  • W Plunkett, P Huang, Gemcitabine Searcy CE et al
  • Semin Oncol 23:S3–S15 326 Invest New Drugs
  • 2012

A phase I and pharmacokinetic study of TAS-106 administered weekly for 3 consecutive weeks every 28 days in patients with solid tumors

  • M Thomas, A Mita, L Hammond
  • Eur J Cancer 38:S25,67a
  • 2002

Similar Papers

Loading similar papers…